Literature DB >> 25697919

Soluble ST2--analytical considerations.

Thomas Mueller1, Allan S Jaffe2.   

Abstract

Suppression of tumorigenicity 2 (ST2, also known as interleukin [IL]-1 receptor-like-1) is an IL-1 receptor family member with transmembrane (ST2L) and soluble isoforms (sST2). ST2L is a membrane-bound receptor, and IL-33 is the functional ligand for ST2L. sST2, a soluble truncated form of ST2L, is secreted into the circulation and functions as a "decoy" receptor for IL-33, inhibiting IL-33/ST2L signaling. Blood concentrations of sST2 are increased in inflammatory diseases and heart disease and are considered a valuable prognostic marker in both conditions. In multiple clinical trials, sST2 has emerged as a clinically useful prognostic biomarker in patients with cardiac diseases. Interestingly, sST2 even provides prognostic information in low-risk community-based populations. In this review, we will discuss analytical considerations of measuring circulating sST2 including pre-analytical issues, such as in vitro stability of sST2, biological variation of sST2, and postanalytical issues, such as reference ranges and comparisons to diseased cohorts.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25697919     DOI: 10.1016/j.amjcard.2015.01.035

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  34 in total

Review 1.  IL-33/ST2 Axis in Organ Fibrosis.

Authors:  Ourania S Kotsiou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Front Immunol       Date:  2018-10-24       Impact factor: 7.561

Review 2.  Biomarkers in heart failure: the past, current and future.

Authors:  Michael Sarhene; Yili Wang; Jing Wei; Yuting Huang; Min Li; Lan Li; Enoch Acheampong; Zhou Zhengcan; Qin Xiaoyan; Xu Yunsheng; Mao Jingyuan; Gao Xiumei; Fan Guanwei
Journal:  Heart Fail Rev       Date:  2019-11       Impact factor: 4.214

3.  The emerging role of sST2 blocking in the therapy of graft-versus-host disease.

Authors:  Yifan Xiao; Fang Zheng
Journal:  Ann Transl Med       Date:  2016-10

4.  Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.

Authors:  Michael R Zile; Pardeep S Jhund; Catalin F Baicu; Brian L Claggett; Burkert Pieske; Adriaan A Voors; Margaret F Prescott; Victor Shi; Martin Lefkowitz; John J V McMurray; Scott D Solomon
Journal:  Circ Heart Fail       Date:  2016-01       Impact factor: 8.790

Review 5.  Interleukin 33 is a guardian of barriers and a local alarmin.

Authors:  Nikolas T Martin; Michael U Martin
Journal:  Nat Immunol       Date:  2016-02       Impact factor: 25.606

Review 6.  Alarmins and Their Receptors as Modulators and Indicators of Alloimmune Responses.

Authors:  B M Matta; D K Reichenbach; B R Blazar; H R Turnquist
Journal:  Am J Transplant       Date:  2016-07-12       Impact factor: 8.086

7.  Association of soluble ST2 with functional capacity in outpatients with heart failure.

Authors:  O Yucel; I Gul; A Zararsiz; O Demirpence; H Yucel; Z Cinar; A Zorlu; M B Yilmaz
Journal:  Herz       Date:  2017-06-26       Impact factor: 1.443

Review 8.  Prognostic biomarkers in acute coronary syndrome.

Authors:  Gian Luca Salvagno; Chiara Pavan
Journal:  Ann Transl Med       Date:  2016-07

9.  Novel interleukin-33 and its soluble ST2 receptor as potential serum biomarkers in parotid gland tumors.

Authors:  Pawel Sowa; Maciej Misiolek; Maciej Zielinski; Bogdan Mazur; Monika Adamczyk-Sowa
Journal:  Exp Biol Med (Maywood)       Date:  2018-05

10.  Elevated ST2 Distinguishes Incidences of Pediatric Heart and Small Bowel Transplant Rejection.

Authors:  L R Mathews; J M Lott; K Isse; A Lesniak; D Landsittel; A J Demetris; Y Sun; D F Mercer; S A Webber; A Zeevi; R T Fischer; B Feingold; H R Turnquist
Journal:  Am J Transplant       Date:  2015-12-11       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.